DGAP-News  299  0 Kommentare curasan AG: curasan presents strategic investor

- Investor with family ties into the Asian medical technology industry
signs ten percent capital increase

- Joint long-term development of the company planned

- Acceleration of sales activities in China and the USA intended

curasan AG (ISIN DE0005494538), a leading specialist for medical products
in the field of bone and tissue regeneration, agreed with a strategic
investor on signing a ten percent capital increase with the subscription
rights of existing shareholders being excluded.

According to the decisions made yesterday evening by the CEO and the
supervisory board of curasan AG the company's share capital from
conditional capital shall be increased at short notice by subscription of
934,604 shares of curasan AG at a price of 1.20 Euros per share by Mr.
Yinan Xiong, born in Beijing (China) and residing in Richmond (British
Columbia, Canada). The payment resulting in the amount of 1,132,324.80
Euros was confirmed by ODDO Seydler Bank AG, which executes the
transaction. Immediately thereafter, the company will apply for the
registration of the implementation of the capital increase, necessary for
the effectiveness. The registration is targeted to take place still in May
2016, i.e. before the annual general meeting of the company on June 23,
2016. Thereby, the registered share capital of curasan AG will be
increased to 1,132,324.80 Euros.

Mr. Yinan Xiong has strong family ties into the Asian producing medical
technology industry. 'From this initial strategic investment in curasan
being the worldwide technology leader in orthobiologic bone regeneration,
numerous synergies will derive in the months and years ahead. Not only in
Asia, but also in western markets', Yinan Xiong explains the rational
behind the investment. 'We noticed the current path of realignment of
curasan leads in the right direction. Together we will now achieve the
goals ahead even faster.'

Following the management change end of 2014, curasan mainly focuses on
optimizing distribution processes of its core products in the field of bone
regeneration, in which the company still sets the worldwide acknowledged
industry standard. In the past months the company successfully refocused
its sales efforts on the most attractive international growth markets and
initiated important registration processes in core markets in Asia and
North-America.

For Michael Schlenk, CEO of curasan AG, the transaction conducted today is